The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $112.15

Today's change-3.11 -2.70%
Updated May 26 4:00 PM EDT. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $112.15

Today's change-3.11 -2.70%
Updated May 26 4:00 PM EDT. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc crosses below 125-day moving average

Intercept Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$3.11 or 2.70% to (U.S.)$112.15 and crossing below its 125-day moving average. Over the last five days, shares are unchanged, but have gained 3.22% over the last year to date. This security has underperformed the S&P 500 by 34.16% during the last year.

Key company metrics

  • Open(U.S.) $115.27
  • Previous close(U.S.) $115.26
  • High(U.S.) $115.95
  • Low(U.S.) $112.00
  • Bid / Ask(U.S.) $112.00 / (U.S.) $118.00
  • YTD % change+3.22%
  • Volume254,591
  • Average volume (10-day)318,194
  • Average volume (1-month)340,393
  • Average volume (3-month)410,451
  • 52-week range(U.S.) $96.63 to (U.S.) $177.93
  • Beta-1.94
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$15.18
Updated May 26 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-825.60%

Although this company's net profit margin is negative, it is above the industry average and implies that Intercept Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.04%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue211456
Total other revenue--------
Total revenue211456
Gross profit21------
Total cost of revenue0------
Total operating expense1051288884
Selling / general / administrative61974442
Research & development44314441
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-84-114-83-78
Interest income (expense), net non-operating-7-7-7--
Gain (loss) on sale of assets--------
Other--------
Income before tax-90-120-89-77
Income after tax-90-120-89-77
Income tax, total--------
Net income-90-120-89-77
Total adjustments to net income--------
Net income before extra. items-90-120-89-77
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-90-120-89-77
Inc. avail. to common incl. extra. items-90-120-89-77
Diluted net income-90-120-89-77
Dilution adjustment0------
Diluted weighted average shares25252525
Diluted EPS excluding extraordinary itemsvalue per share-3.61-4.84-3.59-3.14
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-3.61-4.84-3.59-3.14